Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, "Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation.

“It reflects the continuing and successful research and development that is an essential part of our Company.”

“This new patent further strengthens and secures Biomoda’s market position for early cancer detection,” said John Cousins, Biomoda’s President. “It reflects the continuing and successful research and development that is an essential part of our Company.”

Biomoda's patented cancer and pre-cancer cell based diagnostic assay is trademarked under the name CyPath®. Patent 7,670,799 together with Biomoda’s U.S. patents 6,838,248, entitled "Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" and 7,384,764, entitled "Methods for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" protect the method of detecting cancerous conditions and prognosing responses to cancer therapy with TCPP.

The TCPP platform is the foundation for CyPath®, an in-vitro test for the detection of early-stage lung cancer that currently is completing Phase II clinical trials. Study volunteers have provided deep-lung sputum samples to be screened for cancer with the CyPath® assay in the Biomoda laboratory. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy.

Biomoda is seeking Food and Drug Administration (FDA) approval of CyPath®, its cytology-based screening technology as a Class III medical device. Multisite Phase III trials, the final step before FDA approval, are scheduled to begin in 2010.